Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Auteurs : Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, Von Minckwitz G, Bines J, Garg A
Année : 2019
Journal : Cancer Chemother Pharmacol
Volume : 83
Pages : 1147-1158